Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology

Paul M. Palevsky, Bruce A. Molitoris, Mark D. Okusa, Adeera Levin, Sushrut S. Waikar, Ron Wald, Glenn M. Chertow, Patrick T. Murray, Chirag R. Parikh, Andrew D. Shaw, Alan S. Go, Sarah G. Faubel, John A. Kellum, Vernon M. Chinchilli, Kathleen D. Liu, Alfred K. Cheung, Steven D. Weisbord, Lakhmir S. Chawla, James S. Kaufman, Prasad DevarajanRobert M. Toto, Chi Yuan Hsu, Tom Greene, Ravindra L. Mehta, John B. Stokes, Aliza M. Thompson, B. Taylor Thompson, Christof S. Westenfelder, James A. Tumlin, David G. Warnock, Sudhir V. Shah, Yining Xie, Emily G. Duggan, Paul L. Kimmel, Robert A. Star

Research output: Contribution to journalArticlepeer-review

115 Scopus citations


Acute kidney injury (AKI) remains a complex clinical problem associated with significant short-term morbidity and mortality and lacking effective pharmacologic interventions. Patients with AKI experience longer-term risks for progressive chronic ESRD, which diminish patients' health-related quality of life and create a larger burden on the healthcare system. Although experimental models have yielded numerous promising agents, translation into clinical practice has been unsuccessful, possibly because of issues in clinical trial design, such as delayed drug administration,masking of therapeutic benefit by adverse events, and inadequate sample size. To address issues of clinical trial design, the National Institute of Diabetes and Digestive and Kidney Diseases sponsored a workshop titled "Clinical Trials in Acute Kidney Injury: Current Opportunities and Barriers" in December 2010. Workshop participants included representatives fromacademia, industry, and government agencies whose areas of expertise spanned basic science, clinical nephrology, critical care medicine, biostatistics, pharmacology, and drug development. This document summarizes the discussions of collaborative workgroups that addressed issues related to patient selection, study endpoints, the role of novel biomarkers, sample size and power calculations, and adverse events and pilot/feasibility studies in prevention and treatment of AKI. Companion articles outline the discussions of workgroups for model trials related to prevention or treatment of established AKI in different clinical settings, such as in patients with sepsis.

Original languageEnglish (US)
Pages (from-to)844-850
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Issue number5
StatePublished - May 1 2012

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation


Dive into the research topics of 'Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology'. Together they form a unique fingerprint.

Cite this